Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...

Polycythemia vera (PV), which is marked by an increased number of red blood cells, is a rare blood cancer known to be associated with a high risk of cardiovascular disease. Median survival is ...

Patients diagnosed with polycythemia vera currently have more specialized treatment options that may lead to improved responses to therapy, an expert said. Dr. Jamile M. Shammo, professor of medicine ...

Yesterday the FDA approved Jakafi (Ruxolitinib), a pill, for use in treating polycythemia vera (p. vera). The drug, a targeted kinase inhibitor manufactured by Incyte, offers a needed option for some ...

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera: Osaka, Japan Wednesday, January 7, 2026, 17:00 Hrs [IST] Takeda, focused on c ...

Lipid Profiles Improved in Past Two Decades in United States For patients with polycythemia vera, more intense treatment to achieve a hematocrit target of (HealthDay News) – For patients with ...

The 7MM Polycythemia Vera market size reached approximately USD 1,900 million in 2024 and is projected to grow significantly through 2034. Key players such as Incyte/Novartis, PharmaEssentia/AOP ...

NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG ...